Abstract
Metastases require a functional blood supply for progressive growth. Thus, therapies that target metastatic vasculature have potential clinical utility. The effects of the vascular-targeting agent (VTA), ZD6126, and the anti-angiogenic agent, ZD6474, on vascular development and function within metastases were compared in an experimental liver metastasis model. Ras-transformed PAP2 fibroblasts were injected into the mesenteric veins of SCID mice to produce a control liver metastasis burden of ∼40% at 14 days. Mice given a single dose of ZD6126 (200 mg/kg, i.p.) on day 13 were examined 24 h later. Histology revealed a significant reduction in metastatic burden, associated with extensive tumor necrosis, increased tumor cell apoptosis and a reduction in tumor-associated vasculature. In vivo videomicroscopy (IVVM) revealed disrupted, non-functional vascular channels within metastases, with no blood flow. Mice given ZD6474 on days 4 to 10 (50 mg/kg daily, oral gavage) were examined on day 11. Histology revealed a lower metastatic burden, significant reductions in metastasis size and vasculature, and a significant increase in tumor cell apoptosis. IVVM revealed extensive reductions in vascularity and blood flow within metastases. Neither ZD6126 nor ZD6474 treatment affected surrounding normal liver tissue. This study shows that both agents can reduce experimental liver metastasis with no apparent effect on normal vasculature. However, these reductions were attained through distinct effects on the metastatic vasculature. Understanding differences in the modes of action of VTAs and anti-angiogenic agents will be important in optimizing their clinical application and in developing appropriate combination strategies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–63.
Folkman J. Incipient angiogenesis. J Natl Cancer Inst 2000; 92: 94–5.
Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249–57.
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563–72.
Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505–15.
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727–39.
Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 2003; 41: S63–S72.
Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3: 263–76.
Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415–27.
Micheletti G, Poli M, Borsotti P et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63: 1534–7.
Blakey DC, Ashton SE, Westwood FR et al. ZD6126: A novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54: 1497–502.
Blakey DC, Westwood FR, Walker M et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002; 8: 1974–83.
Goto H, Yano S, Zhang H et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002; 62: 3711–5.
Davis PD, Dougherty GJ, Blakey DC et al. ZD6126: A novel vasculartargeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62: 7247–53.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–76.
Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003; 9: 1604–6.
Mukherjee T, Kumar A, Mathur M et al. Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003: 129: 430–6.
Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–55.
Varghese HJ, Davidson MT, MacDonald IC et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62: 887–91.
Varghese HJ, MacKenzie LT, Ellis CG et al. In vivo quantification of functional microcirculation in liver metastases. Proc Am Assoc Cancer Res 2003; 44: 779.
Japee SA, Ellis CG, Pittman RN. Flow visualization tools for image analysis of capillary networks. Microcirculation 2004; 11: 39–54.
Weibel ER. Profile size and particle size. In Weibel ER (ed): Stereological Methods: Practical Methods for Biological Morphometry, Vol. 1. New York: Academic Press 1979; 51–60.
Luzzi KJ, Varghese HJ, MacDonald IC et al. Inhibition of angiogenesis in liver metastases by carboxyamidotriazole (CAI). Angiogenesis 1999; 2: 373–9.
Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 53: 164–71.
Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002; 54: 1512–7.
Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546–56.
Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy: Schedule-dependent enhancement of anti-tumor activity in a lung tumor xenograft model. Proc Am Assoc Cancer Res 2003; 44: 8.
Wedge SR, Kendrew J, Ogilvie DJ et al. Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. Proc Am Assoc Cancer Res 2002; 43: 1081.
Gieseler F, Rudolph P, Kloeppel G, Foelsch UR. Resistance mechanisms of gastrointestinal cancers: Why does conventional chemotherapy fail? Int J Colorectal Dis 2003; 18: 470–80.
Broxterman HJ, Lankelma J, Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: Similarities and differences. Drug Resist Updat 2003; 6: 111–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Varghese, H., Mackenzie, L., Groom, A. et al. In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 7, 157–164 (2004). https://doi.org/10.1007/s10456-004-1941-3
Issue Date:
DOI: https://doi.org/10.1007/s10456-004-1941-3